Exelixis Inc (NQ: EXEL )
22.25
-0.01
(-0.02%)
Streaming Delayed Price
Updated: 12:23 PM EDT, Jun 26, 2024
Add to My Watchlist
All News about Exelixis Inc
![](https://mms.businesswire.com/media/20221101005381/en/610803/5/exelixis_id_rgb_2c.jpg)
Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 01, 2022
From Exelixis, Inc.
Via Business Wire
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_6692.png?width=1200&height=800&fit=crop)
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/09/08/aapharma_13.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/earnings_image_604.png?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2021/06/Stock-Exelixis-01-shutt.jpg)
![](https://g.foolcdn.com/editorial/images/706031/bear-market-stocks-plunge-crash-invest-correction-getty.jpg)
![](https://g.foolcdn.com/editorial/images/706113/cancer-patient-flexing-muscle.jpg)
![](https://mms.businesswire.com/media/20221025006078/en/611316/5/Exelixis_Logo_JPG.jpg)
![](https://g.foolcdn.com/editorial/images/704941/a-family-meeting-with-an-advisor.jpg)
![](https://mms.businesswire.com/media/20221018006164/en/610803/5/exelixis_id_rgb_2c.jpg)
Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022
October 18, 2022
From Exelixis, Inc.
Via Business Wire
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_5803.png?width=1200&height=800&fit=crop)
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2022
October 18, 2022
Via Benzinga
![](https://g.foolcdn.com/editorial/images/704469/plants-on-coins.jpeg)
![](https://investorplace.com/wp-content/uploads/2021/11/shutterstock_1667119063.png)
![](https://mms.businesswire.com/media/20220929005808/en/611316/5/Exelixis_Logo_JPG.jpg)
![](https://investorplace.com/wp-content/uploads/2021/03/biotech-stocks-2.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/09/12/aapharma_3.png?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20220909005430/en/611316/5/Exelixis_Logo_JPG.jpg)
![](https://mms.businesswire.com/media/20220906006098/en/611316/5/Exelixis_Logo_JPG.jpg)
![](https://mms.businesswire.com/media/20220906005958/en/610803/5/exelixis_id_rgb_2c.jpg)
From Exelixis, Inc.
Via Business Wire
![](https://www.investors.com/wp-content/uploads/2017/08/HTI-WALLSTREET-adobe.jpg)
![](https://mms.businesswire.com/media/20220808005783/en/610803/5/exelixis_id_rgb_2c.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/08/09/biotech7.jpg?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20220726005948/en/610803/5/exelixis_id_rgb_2c.jpg)
![](https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715.png)
![](https://mms.businesswire.com/media/20220710005054/en/611316/5/Exelixis_Logo_JPG.jpg)
![](https://investorplace.com/wp-content/uploads/2019/07/biotech1600d.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/07/07/screen_shot_2022-07-07_at_10.02.51_am.png?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20220706005879/en/1506638/5/logo_RYVU_z_dopiskiem_Obszar_roboczy_1.jpg)
![](https://mms.businesswire.com/media/20220705005718/en/610803/5/exelixis_id_rgb_2c.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_17039.jpeg?width=1200&height=800&fit=crop)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.